CAH insider sale notice: 13,500 shares via Merrill on 08/19/2025
Rhea-AI Filing Summary
Cardinal Health Form 144 notice: The filing reports a proposed sale of 13,500 shares of common stock through Merrill (Columbus, OH) with an aggregate market value of $2,009,030. The securities are listed on the NYSE and total shares outstanding are reported as 238,793,647. The approximate sale date is 08/19/2025. The shares to be sold were acquired mostly on 08/15/2025 as restricted and performance stock vesting (3,863 restricted; 9,318 performance) and a smaller tranche on 02/15/2025 (319 restricted).
The filer certifies there are no undisclosed material adverse facts and notes no sales in the past three months. This is a routine insider sale notice required under Rule 144 describing the broker, quantity, acquisition dates and nature of acquisition.
Positive
- Complete transaction detail provided: broker, share count, aggregate value, exchange and approximate sale date are all disclosed
- Acquisition types disclosed: restricted stock and performance stock vesting dates are listed, improving transparency
- No prior sales reported in the past three months, simplifying Rule 144 aggregation
Negative
- None.
Insights
TL;DR: Routine Rule 144 notice for a modest insider sale; provides standard disclosure of vested shares and broker details.
The filing documents a proposed disposition of 13,500 Cardinal Health common shares via Merrill with market value shown at $2,009,030 and an expected sale date of 08/19/2025. Acquisition details list restricted and performance stock vesting on 08/15/2025 and a small restricted grant on 02/15/2025. No sales reported in the prior three months. This is a compliance-focused disclosure that gives investors transparency into insider liquidity but does not itself provide operational or financial performance information.
TL;DR: Disclosure meets Rule 144 elements; the representation about no undisclosed material information is standard and important for compliance.
The notice includes the seller relationship to the issuer, broker identity, share counts, acquisition dates and types (restricted and performance stock vesting), and a certification about material information. Such filings are typical when insiders sell vested equity and serve to document compliance with securities-law resale conditions. The absence of reported sales in the prior three months simplifies aggregation considerations under Rule 144.